Organ-on-a-Chip Drug Testing Platform OrganChip Receives EMA Approval: Preclinical Drug Testing Shortened from 3 Years to 6 Months
Emulate's organ-on-a-chip drug testing platform OrganChip receives EMA regulatory approval, enabling it to replace certain animal experiments for preclinical drug safety assessment with significantly shorter testing cycles
Organ-on-a-Chip Drug Testing Platform OrganChip Receives EMA Approval: Preclinical Drug Testing Shortened from 3 Years to 6 Months
Emulate announced on October 7 that its organ-on-a-chip drug testing platform OrganChip has received regulatory approval from the European Medicines Agency. This means OrganChip's test data can serve as formal evidence for preclinical drug safety assessment, partially replacing traditional animal experiments.
OrganChip is a microfluidic chip that cultivates human organ cells on a fingernail-sized chip, simulating the microenvironment of real organs. Each chip contains five organ modules — liver, kidney, heart, lung, and intestine — connected by microfluidic channels to form a "human-on-a-chip." After running drugs on the chip, the system can simultaneously evaluate toxicity and metabolic effects on all five organs.
In comparative testing against traditional animal experiments, OrganChip achieved a 91% prediction accuracy for drug hepatotoxicity, higher than the 72% accuracy of animal experiments. The EMA's regulatory approval will significantly shorten preclinical drug testing cycles — from the traditional 2-3 years to approximately 6 months. Multiple pharmaceutical giants have announced plans to adopt OrganChip as their standard preclinical testing platform.
Disclaimer
Content is AI-generated. Do not use it as a basis for real decisions. Do not cite it as factual reporting.